



2007-06-19

Pressrelease

Oasmia presents Paclical® Vet in Budapest

The pharmaceutical company Oasmia Pharmaceutical will present results from a phase I/II study with the cancer product Paclical® Vet at the Veterinary European ECVIM-CA Congress 13-15 September in Budapest. The results have been presented earlier and have reached great international interest.

More information is available at www.ngm.se or www.oasmia.com. For further information contact info@oasmia.com or call +46 18 50 54 40.

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. Oasmia develops pharmaceuticals for the future.

A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is noted on NGM Nordic MTF. Planning to change list to NGM Equity in September 2007.